Europe Rare Neurological Disease Treatment Market to Grow at a CAGR of 8.1% to reach US$ 3,763.41 Million from 2019 to 2027

1. Introduction

1.1 Business Market Insights Research Report Guidance

1.2 Market Segmentation

2. Executive Summary

2.1 Key Market Insights

2.2 Market Attractiveness

3. Research Methodology

3.1 Secondary Research

3.2 Primary Research

3.2.1 Hypothesis formulation:
3.2.2 Macro-economic factor analysis:
3.2.3 Developing base number:
3.2.4 Data Triangulation:
3.2.5 Country level data:

4. Europe Rare Neurological Disease Treatment Market Landscape

4.1 Market Overview

4.2 Porter's Five Forces Analysis

4.2.1 Bargaining Power of Suppliers
4.2.2 Bargaining Power of Buyers
4.2.3 Threat of New Entrants
4.2.4 Competitive Rivalry
4.2.5 Threat of Substitutes

4.3 Ecosystem Analysis

4.3.1 Raw Material Suppliers
4.3.2 Manufacturers
4.3.3 Distributors/Suppliers
4.3.4 End Users

5. Europe Rare Neurological Disease Treatment Market – Key Market Dynamics

5.1 Growth Drivers

5.1.1 Innovative Therapies Rare Neurological Disease Treatment

5.2 Market Opportunities

5.2.1 Product Launches to Favor Market

5.3 Future Trends

5.3.1 Clinical trials and drug research to treat rare neurological disease treatment

5.4 Impact of Drivers and Restraints

6. Europe Rare Neurological Disease Treatment Market Regional Analysis

6.1 Europe Rare Neurological Disease Treatment Market Overview

6.2 Europe Rare Neurological Disease Treatment Market Revenue 2017-2027 (US$ Million)

6.3 Europe Rare Neurological Disease Treatment Market Forecast Analysis

7. Europe Rare Neurological Disease Treatment Market Analysis – by Indication

7.1 Narcolepsy

7.1.1 Overview
7.1.2 Narcolepsy: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)

7.2 Amyotrophic Lateral Sclerosis

7.2.1 Overview
7.2.2 Amyotrophic Lateral Sclerosis: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)

7.3 Alzheimer's Disease

7.3.1 Overview
7.3.2 Alzheimer's Disease: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)

7.4 Multiple Sclerosis

7.4.1 Overview
7.4.2 Multiple Sclerosis: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)

7.5 Spinal Muscular Atrophy

7.5.1 Overview
7.5.2 Spinal Muscular Atrophy: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)

7.6 Duchenne Muscular Dystrophy

7.6.1 Overview
7.6.2 Duchenne Muscular Dystrophy: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)

7.7 Other Indication

7.7.1 Overview
7.7.2 Other Indication: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2031 (US$ Million)

8. Europe Rare Neurological Disease Treatment Market Analysis – by Drug Type

8.1 Organic Compounds

8.1.1 Overview
8.1.2 Organic Compounds: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

8.2 Biologics

8.2.1 Overview
8.2.2 Biologics: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

9. Europe Rare Neurological Disease Treatment Market Analysis – by Distribution Channel

9.1 Online Pharmacies

9.1.1 Overview
9.1.2 Biologics: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

9.2 Hospital Pharmacies

9.2.1 Overview
9.2.2 Biologics: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

9.3 Retail Pharmacies

9.3.1 Overview
9.3.2 Biologics: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

10. Europe Rare Neurological Disease Treatment Market – Europe Analysis

10.1 Europe

10.1.1 Europe Rare Neurological Disease Treatment Market Breakdown, by Key Country, 2020 and 2027 (%)
10.1.1.1 Europe Rare Neurological Disease Treatment Market – Revenue and Forecast Analysis – by Country
10.1.1.1 UK: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.1.1 UK: Europe Rare Neurological Disease Treatment Market Breakdown, by Indication
10.1.1.1.2 UK: Europe Rare Neurological Disease Treatment Market Breakdown, by Drug Type
10.1.1.1.3 UK: Europe Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel

10.1.1.2 Germany: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.2.1 Germany: Europe Rare Neurological Disease Treatment Market Breakdown, by Indication
10.1.1.2.2 Germany: Europe Rare Neurological Disease Treatment Market Breakdown, by Drug Type
10.1.1.2.3 Germany: Europe Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel

10.1.1.3 France: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.3.1 France: Europe Rare Neurological Disease Treatment Market Breakdown, by Indication
10.1.1.3.2 France: Europe Rare Neurological Disease Treatment Market Breakdown, by Drug Type
10.1.1.3.3 France: Europe Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel

10.1.1.4 Russia: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.4.1 Russia: Europe Rare Neurological Disease Treatment Market Breakdown, by Indication
10.1.1.4.2 Russia: Europe Rare Neurological Disease Treatment Market Breakdown, by Drug Type
10.1.1.4.3 Russia: Europe Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel

10.1.1.5 Italy: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.5.1 Italy: Europe Rare Neurological Disease Treatment Market Breakdown, by Indication
10.1.1.5.2 Italy: Europe Rare Neurological Disease Treatment Market Breakdown, by Drug Type
10.1.1.5.3 Italy: Europe Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel

10.1.1.6 Rest of Europe: Europe Rare Neurological Disease Treatment Market – Revenue and Forecast to 2027 (US$ Million)

10.1.1.6.1 Rest of Europe: Europe Rare Neurological Disease Treatment Market Breakdown, by Indication
10.1.1.6.2 Rest of Europe: Europe Rare Neurological Disease Treatment Market Breakdown, by Drug Type
10.1.1.6.3 Rest of Europe: Europe Rare Neurological Disease Treatment Market Breakdown, by Distribution Channel

11. Competitive Landscape

11.1 Heat Map Analysis

11.2 Company Positioning and Concentration

12. Europe Rare Neurological Disease Treatment Market Industry Landscape

12.1 Overview

12.2 Mergers and Acquisitions

12.3 Agreements, Collaborations, and Joint Ventures

12.4 New Product Launches

12.5 Expansions and Other Strategic Developments

13. Company Profiles

13.1 Allergan plc.

13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments

13.2 Bayer AG

13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments

13.3 GlaxoSmithKline plc.

13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments

13.4 Johnson & Johnson Services Inc.

13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments

13.5 Merck & Co. Inc.

13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments

13.6 Novartis AG

13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments

13.7 Pfizer Inc.

13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments

13.8 Sanofi

13.8.1 Key Facts
13.8.2 Business Description
13.8.3 Products and Services
13.8.4 Financial Overview
13.8.5 SWOT Analysis
13.8.6 Key Developments

13.9 Teva Pharmaceutical Industries Ltd

13.9.1 Key Facts
13.9.2 Business Description
13.9.3 Products and Services
13.9.4 Financial Overview
13.9.5 SWOT Analysis
13.9.6 Key Developments

13.10 Takeda Pharmaceutical Company Limited

13.10.1 Key Facts
13.10.2 Business Description
13.10.3 Products and Services
13.10.4 Financial Overview
13.10.5 SWOT Analysis
13.10.6 Key Developments

14. Appendix

14.1 About Business Market Insights